Compare PRKS & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRKS | ANIP |
|---|---|---|
| Founded | 1959 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2012 | 1999 |
| Metric | PRKS | ANIP |
|---|---|---|
| Price | $31.09 | $73.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | $46.40 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 955.4K | 345.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | 3.06 | ★ 3.32 |
| Revenue | ★ $1,263,324,000.00 | $206,547,000.00 |
| Revenue This Year | $3.88 | $23.05 |
| Revenue Next Year | $3.07 | $14.08 |
| P/E Ratio | ★ $10.22 | $22.52 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $29.62 | $56.71 |
| 52 Week High | $56.95 | $99.50 |
| Indicator | PRKS | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 43.32 |
| Support Level | $29.85 | $71.29 |
| Resistance Level | $37.12 | $84.47 |
| Average True Range (ATR) | 1.24 | 2.35 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 22.31 | 45.56 |
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.